Evidence map›Paper›PMID 40814068›Full record

ReviewTropical diseases, travel medicine and vaccines2025

The emerging role of Imatinib in malaria management: a review of evidence and future directions.

Victor Oluwatomiwa Ajekiigbe, Chidera Stanley Anthony, Ikponmwosa Jude Ogieuhi, Jonathan Oluwafemi Adeola, Peace Uchechi Bassey, Pelumi Gbolagade-Jonathan, Stephen Olaide Aremu, Akintunde Abisoye Omoleke, Ifeoluwa Sandra Bakare, Adedoyin Veronica Babalola

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tropical diseases, travel medicine and vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Victor Oluwatomiwa AjekiigbeLadoke Akintola University of Technology, Ogbomosho, Nigeria.
Chidera Stanley AnthonyUniversity of Calabar, Calabar, Nigeria.
Ikponmwosa Jude OgieuhiSiberian State Medical University, Tomsk, Russia.
Jonathan Oluwafemi AdeolaLadoke Akintola University of Technology, Ogbomosho, Nigeria.
Peace Uchechi BasseySchool of Public Health, University of Port Harcourt, Port Harcourt, Nigeria.
Pelumi Gbolagade-JonathanUniversity of Ibadan, Ibadan, Oyo State, Nigeria.
Stephen Olaide AremuGlobal Health and Infectious Disease Control Institute, Nasarawa State University, Keffi, Nasarawa State, Nigeria.
Akintunde Abisoye OmolekeLadoke Akintola University of Technology, Ogbomosho, Nigeria.
Ifeoluwa Sandra BakareTernopil State Medical University, Ternopil, Ukraine. Bakaresandra9@gmail.com.
Adedoyin Veronica BabalolaUniversity of Ibadan, Ibadan, Oyo State, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalaria still remains one of the leading causes of death, especially in Africa, with one of the major struggles associated with eradication being resistance to antimalarial medications. Imatinib, a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia, has emerged as a potential pharmacological approach for malaria management.

methodsThis review synthesizes studies from the inception of the databases of PubMed, Scopus, Google Scholar, Cochrane, Web of Science, and Embase to February 2025, identifying key clinical trials and invitro studies conducted to assess the efficacy and safety of Imatinib in malaria.

resultsWith varying sample sizes, dosage and follow-up data, the studies reported a decline in parasite density, pyrexia, parasite growth inhibition, and synergism with other anti-malarial medications like Artesunate. Across the nine (9) studies reviewed, Imatinib showed a favorable safety profile with no adverse drug-related events reported.

conclusionsWe discuss the potential advantages and challenges of repurposing Imatinib for treating malaria, its pharmacokinetic profile, and its use in other patient populations, such as children and pregnant women. Future studies should focus on randomized controlled trials with larger sample sizes and possible combination therapies with other antimalarial medications.

Indexed as

ImatinibMalaria eradicationPlasmodiumsub-Saharan Africa

Identifiers

PMID40814068
PMCPMC12355833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.